Logo image of GELS

GELTEQ LTD (GELS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GELS - AU0000218109 - Common Stock

1.1 USD
+0.02 (+1.85%)
Last: 12/4/2025, 8:25:30 PM
0.9794 USD
-0.12 (-10.96%)
Pre-Market: 12/5/2025, 7:22:32 AM
Fundamental Rating

1

GELS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of GELS have multiple concerns. GELS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GELS has reported negative net income.
GELS Yearly Net Income VS EBIT VS OCF VS FCFGELS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

Looking at the Return On Assets, with a value of -14.12%, GELS is in the better half of the industry, outperforming 63.54% of the companies in the same industry.
With a decent Return On Equity value of -18.87%, GELS is doing good in the industry, outperforming 68.23% of the companies in the same industry.
Industry RankSector Rank
ROA -14.12%
ROE -18.87%
ROIC N/A
ROA(3y)-15.69%
ROA(5y)N/A
ROE(3y)-19.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GELS Yearly ROA, ROE, ROICGELS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GELS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GELS Yearly Profit, Operating, Gross MarginsGELS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

GELS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GELS remains at a similar level compared to 1 year ago.
Compared to 1 year ago, GELS has a worse debt to assets ratio.
GELS Yearly Shares OutstandingGELS Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M
GELS Yearly Total Debt VS Total AssetsGELS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of 0.46, we must say that GELS is in the distress zone and has some risk of bankruptcy.
GELS has a Altman-Z score (0.46) which is comparable to the rest of the industry.
GELS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.00, GELS is doing good in the industry, outperforming 63.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.46
ROIC/WACCN/A
WACC8.47%
GELS Yearly LT Debt VS Equity VS FCFGELS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

GELS has a Current Ratio of 0.79. This is a bad value and indicates that GELS is not financially healthy enough and could expect problems in meeting its short term obligations.
GELS has a Current ratio of 0.79. This is amonst the worse of the industry: GELS underperforms 89.06% of its industry peers.
GELS has a Quick Ratio of 0.79. This is a bad value and indicates that GELS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of GELS (0.79) is worse than 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
GELS Yearly Current Assets VS Current LiabilitesGELS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M

More info and screens

0

3. Growth

3.1 Past

GELS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.13%.
The Revenue for GELS has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-1.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GELS Yearly Revenue VS EstimatesGELS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 50K 100K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GELS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GELS Price Earnings VS Forward Price EarningsGELS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GELS Per share dataGELS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GELS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GELTEQ LTD

NASDAQ:GELS (12/4/2025, 8:25:30 PM)

Premarket: 0.9794 -0.12 (-10.96%)

1.1

+0.02 (+1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-17 2025-11-17
Earnings (Next)N/A N/A
Inst Owners1.05%
Inst Owner ChangeN/A
Ins Owners46%
Ins Owner ChangeN/A
Market Cap11.78M
Revenue(TTM)N/A
Net Income(TTM)-3.55M
AnalystsN/A
Price TargetN/A
Short Float %0.04%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.16
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.12%
ROE -18.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-15.69%
ROA(5y)N/A
ROE(3y)-19.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z 0.46
F-ScoreN/A
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.53%
OCF growth 3YN/A
OCF growth 5YN/A

GELTEQ LTD / GELS FAQ

Can you provide the ChartMill fundamental rating for GELTEQ LTD?

ChartMill assigns a fundamental rating of 1 / 10 to GELS.


What is the valuation status for GELS stock?

ChartMill assigns a valuation rating of 0 / 10 to GELTEQ LTD (GELS). This can be considered as Overvalued.


Can you provide the profitability details for GELTEQ LTD?

GELTEQ LTD (GELS) has a profitability rating of 1 / 10.


What is the financial health of GELTEQ LTD (GELS) stock?

The financial health rating of GELTEQ LTD (GELS) is 1 / 10.